FI941133A - Koostumus ja menetelmä hepatiitti C:n hoitamiseksi - Google Patents

Koostumus ja menetelmä hepatiitti C:n hoitamiseksi Download PDF

Info

Publication number
FI941133A
FI941133A FI941133A FI941133A FI941133A FI 941133 A FI941133 A FI 941133A FI 941133 A FI941133 A FI 941133A FI 941133 A FI941133 A FI 941133A FI 941133 A FI941133 A FI 941133A
Authority
FI
Finland
Prior art keywords
thymosin
hepatitis
procedure
treatment
composition
Prior art date
Application number
FI941133A
Other languages
English (en)
Swedish (sv)
Other versions
FI941133A0 (fi
FI107879B (fi
Inventor
Milton Mutchnick
Original Assignee
Alpha 1 Biomedicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 1 Biomedicals Inc filed Critical Alpha 1 Biomedicals Inc
Publication of FI941133A0 publication Critical patent/FI941133A0/fi
Publication of FI941133A publication Critical patent/FI941133A/fi
Application granted granted Critical
Publication of FI107879B publication Critical patent/FI107879B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
FI941133A 1991-09-13 1994-03-10 Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi FI107879B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13
US75954491 1991-09-13
US9207556 1992-09-08
PCT/US1992/007556 WO1993005806A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c

Publications (3)

Publication Number Publication Date
FI941133A0 FI941133A0 (fi) 1994-03-10
FI941133A true FI941133A (fi) 1994-03-10
FI107879B FI107879B (fi) 2001-10-31

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941133A FI107879B (fi) 1991-09-13 1994-03-10 Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi

Country Status (23)

Country Link
US (3) US6001799A (fi)
EP (1) EP0603305B1 (fi)
JP (1) JP3228512B2 (fi)
KR (1) KR100254082B1 (fi)
AT (1) ATE152914T1 (fi)
AU (1) AU667327B2 (fi)
CA (1) CA2119006C (fi)
CZ (1) CZ286827B6 (fi)
DE (1) DE69219782T2 (fi)
DK (1) DK0603305T3 (fi)
ES (1) ES2103966T3 (fi)
FI (1) FI107879B (fi)
GR (1) GR3024025T3 (fi)
HK (1) HK1021687A1 (fi)
HU (1) HU221006B1 (fi)
MX (1) MX9205240A (fi)
NO (1) NO941310D0 (fi)
RO (1) RO111991B1 (fi)
RU (1) RU2104010C1 (fi)
SG (1) SG64897A1 (fi)
TW (1) TW224053B (fi)
WO (1) WO1993005806A1 (fi)
ZA (1) ZA926964B (fi)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (fi) * 1991-09-13 1994-05-21 Paul B Chretien
EP0728010A4 (en) * 1992-02-06 1997-10-01 Sciclone Pharmaceuticals METHOD FOR TREATING HEPATITIS B CARRIERS WITH A MINOR DISEASE
WO1994001125A1 (en) * 1992-07-13 1994-01-20 Sherman Kenneth E Composition and method of treating hepatitis b
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
PT731710E (pt) * 1993-11-05 2003-09-30 Sciclone Pharmaceuticals Inc Composicoes contendo timosine alpha 1 destinadas ao tratamento de pacientes sofrendo duma doenca de figado descompensado
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
KR100394382B1 (ko) * 1996-02-28 2004-02-05 유니하트 코포레이션 천연사람α-인터페론으로구성된약학조성물
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
KR100851861B1 (ko) * 2000-08-07 2008-08-13 사이클론 파아머슈티컬 인코오퍼레이티드 티모신, 인터페론 및 리바비린을 사용한 씨 형 간염의치료
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
CA2460341A1 (en) * 2001-10-05 2003-04-17 Intermune, Inc. Methods of treating liver fibrosis and hepatitis c virus infection
UA81613C2 (ru) 2001-10-26 2008-01-25 Род Айленд Хоспитл Стимуляция тимозином генетической иммунизации
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
NZ534811A (en) * 2002-02-14 2007-07-27 Pharmasset Inc Modified fluorinated nucleoside analogues
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
ES2469569T3 (es) 2002-06-28 2014-06-18 Idenix Pharmaceuticals, Inc. Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
JP5116972B2 (ja) 2002-12-12 2013-01-09 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドの製造方法
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
EA008037B1 (ru) * 2003-03-28 2007-02-27 Сциклон Фармасьютикалс, Инк. ЛЕЧЕНИЕ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ГРИБАМИ p. ASPERGILLUS, С ПОМОЩЬЮ ТИМОЗИНА АЛЬФА 1
ES2345552T3 (es) * 2003-03-28 2010-09-27 Sciclone Pharmaceuticals, Inc. Tratamiento de infecciones por aspergillus con timosina alfa 1.
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
EP3521297B1 (en) 2003-05-30 2021-12-22 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
EP1658302B1 (en) * 2003-07-25 2010-08-25 IDENIX Pharmaceuticals, Inc. Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
WO2005107742A1 (en) 2004-05-05 2005-11-17 Yale University Novel antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
RU2433124C2 (ru) 2004-09-14 2011-11-10 Фармассет, Инк. Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US7781576B2 (en) 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
SI2012816T1 (sl) * 2006-05-02 2012-09-28 Sigma Tau Ind Farmaceuti Uporaba timozina 1, samega ali v kombinaciji s PTX3 ali ganciklovirjem, za zdravljenje citomegalovirusne infekcije
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20110195048A1 (en) * 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
CL2009002208A1 (es) 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
US8716012B2 (en) 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
KR101715981B1 (ko) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 뉴클레오사이드 포스포르아미데이트
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (fi) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
CZ286827B6 (cs) 2000-07-12
RU2104010C1 (ru) 1998-02-10
ZA926964B (en) 1993-04-26
HU221006B1 (hu) 2002-07-29
DE69219782T2 (de) 1997-10-09
DK0603305T3 (da) 1997-09-01
ES2103966T3 (es) 1997-10-01
CZ55194A3 (en) 1994-10-19
US20070218033A1 (en) 2007-09-20
FI941133A0 (fi) 1994-03-10
HK1021687A1 (en) 2000-06-23
EP0603305B1 (en) 1997-05-14
GR3024025T3 (en) 1997-10-31
CA2119006A1 (en) 1993-04-01
US5849696A (en) 1998-12-15
NO941310L (no) 1994-04-12
RO111991B1 (ro) 1997-04-30
SG64897A1 (en) 1999-05-25
HUT75166A (en) 1997-04-28
CA2119006C (en) 2005-08-23
EP0603305A1 (en) 1994-06-29
TW224053B (fi) 1994-05-21
RU94022480A (ru) 1996-07-20
FI107879B (fi) 2001-10-31
US6001799A (en) 1999-12-14
AU2644792A (en) 1993-04-27
JPH06510998A (ja) 1994-12-08
DE69219782D1 (de) 1997-06-19
HU9400758D0 (en) 1994-06-28
NO941310D0 (no) 1994-04-12
WO1993005806A1 (en) 1993-04-01
KR100254082B1 (ko) 2000-09-01
ATE152914T1 (de) 1997-05-15
AU667327B2 (en) 1996-03-21
JP3228512B2 (ja) 2001-11-12
MX9205240A (es) 1993-07-01

Similar Documents

Publication Publication Date Title
FI941133A (fi) Koostumus ja menetelmä hepatiitti C:n hoitamiseksi
FI953608A0 (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalvossa järjestelmällisellä rokottamisella
DK0380230T3 (da) Immunogene sammensætninger mod gastrin-peptider
DE69127437D1 (de) Stickoxide zur gewichtsreduktion
NO883896L (no) Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.
AU4205789A (en) Method and composition for the treatment and prevention of viral infections
FI924363A0 (fi) Foerfarande foer behandling och/eller diagnostisering av mjukvaevnadstumoerer.
SG46620A1 (en) Method and composition foor the treatment of autoimmune hepatitis
DK0396903T3 (da) Anvendelse af IFN-gamma til fremstilling af et farmaceutisk præparat til behandling af ATL
ATE76579T1 (de) Interferon-zusammensetzungen.
FI972929A (fi) Kollageeniin perustuvia menetelmiä ja koostumuksia immuunijärjestelmän välittämien sairauksien hoitamiseksi
DE3750886D1 (de) Verwendung eines immunglobulinhaltigen Präparates zur Prophylaxe und Therapie von AIDS beim Menschen.
NO953473L (no) Fremgangsmåte for behandling av hepatitt C i individer som er ikke-respondere overfor interferonbehandling
AU4829190A (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
NO933628D0 (no) Fremgangsmaate og blanding for behandling av herpes-infeksjoner
MY110041A (en) Composition and method of treating hepatitis c
MY109685A (en) Method for treating hepatitis b carriers with minimal disease
SE9304284D0 (sv) Sätt och anordning för behandling av aska
NO169182C (no) Doseringsbeholder for opptak og levering av midler for behandling av toey.
ZA897105B (en) Method and composition for the treatment of viral infections
SE9101471D0 (sv) Foerfarande foer tillverkning av byggelement och byggelement tillverkat enligt foerfarandet

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: ALPHA 1 BIOMEDICALS, INC.

GB Transfer or assigment of application

Owner name: ALPHA 1 BIOMEDICALS, INC.

MM Patent lapsed